Catalym logo.jpg.png
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
May 04, 2021 05:00 ET | CatalYm GmbH
MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief...
22157.jpg
Global Allergy Treatment Market Report 2021: Market is Expected to Reach $35.81 Billion by 2028 - Development and Approvals of Innovative Medicines such as Biologics Gaining Momentum
April 29, 2021 07:33 ET | Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food...
Cytovia.png
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
April 28, 2021 13:16 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
April 28, 2021 12:35 ET | Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...
biracell-logo-new.png
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
April 21, 2021 08:00 ET | Briacell Therapeutics Corp.
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics...
22157.jpg
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
April 19, 2021 08:18 ET | Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...
Cellectis Logo.png
Monthly information on share capital and company voting rights
April 12, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Cytovia.png
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
April 12, 2021 11:11 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cello logo (transparent background).png
Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment
March 31, 2021 22:57 ET | Cello Therapeutics, Inc.
SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute....
New Logo.png
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
March 31, 2021 07:00 ET | Provectus Biopharmaceuticals Inc.
46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...